A self-assembled supramolecular organic material for selective extraction of uranium from aqueous solution

Journal of Radioanalytical and Nuclear Chemistry - A supramolecular organic material MA-IPA containing melamine and isophthalic acid was prepared by low-temperature hydrothermal reaction, with an...     

Indium-111 labeled bleomycin for targeting diagnosis and therapy of liver tumor: optimized preparation,biodistribution and SPECT imaging with xenograft models

In this work, the preparation of ¹¹¹In radiolabeled bleomycin (¹¹¹In-BLM) was optimized systematically and used for SPECT imaging of liver cancer xenograft models. ¹¹¹In-BLM with a high radiochemical yield (>?99%) could be obtained at pH 0.5–1 at a mixture ratio of 9:1 (¹¹¹In/BLM, mCi/mg). The radiochemical purity of ¹¹¹In-BLM retained?>?99% in either buffers or serum for 3 days. Biodistribution of ¹¹¹In-BLM revealed its excellent stability in vivo. The SPECT imaging studies showed ¹¹¹In-BLM has great specificity to liver tumor xenograft. All the results implied ¹¹¹In-BLM is a potential radiopharmaceutical for targeting diagnosis and therapy of liver tumor.

     

In Vitro Anticancer Ability of Nano Fluorescent 111In-MIL-68/PEG-FA on Hela Cells

In past decades, nanoscale metal-organic frameworks (NMOFs) have drawn more and more attention in multimodal imaging and targeting therapy of various malignant cancers. Here, we proposed to dope ¹¹¹In into fluorescent In-based NMOFs (In-MIL-68-NH₂), with an attempt to prepare a new nanomedicine with great anticancer potential. As a proof of concept, the obtained NMOF (In-MIL-68/PEG-FA) with targeting motifs is able to act as a fluorescent probe to achieve Hela cell imaging. Moreover, the Auger electron emitter ¹¹¹In built in corresponding radioactive NMOF (¹¹¹In-MIL-68/PEG-FA) can bring clear damage to cancer cells, leading to a high cell killing rate of 59.3 % within 48 h. In addition, the cell cycle presented a significant dose-dependent G2/M inhibiting mode, which indicates that ¹¹¹In-MIL-68/PEG-FA has the ability to facilitate the cancer cells to enter apoptotic program. This work demonstrated the potential of ¹¹¹In-labelled NMOFs in specific killings of cancer cells, providing a new approach to develop nanomedicines with theranostic function.     

加速器生产医用同位素211At及单抗标记

²¹¹At, 半衰期7.2 h, 发射的α粒子具有很高的线性传能密度, 是一种理想的靶向α治疗核素. 利用中国科学院近代物理研究所强流超导直线加速器提供的α束流辐照Bi靶生产²¹¹At, 系统考察了加速器生产²¹¹At的整个流程, 包括加速器辐照、干蒸馏分离、质量分析以及单抗标记. 研究结果表明, 干蒸馏分离²¹¹At的总收率最高达78.53%, 获得的固体²¹¹At产品具有极高的比活度、核纯度以及化学纯度, 其中杂质元素Bi、Cu、Zn、Al含量均低于100 ng/GBq, 且入射粒子能量低于28.2 MeV时, N(²¹⁰At)/N(²¹¹At)值低于10^–5, 研究也实现了²¹¹At在尼妥珠单抗上的标记, 标记率高达94.86%. 基于以上研究我们确立了一套简单、高效的分离方法, 为后续我国²¹¹At的生产和应用奠定了良好基础.